ArticlePloS one2010
Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- The role of sclerostin and osteoprotegerin in bone metabolism in children with congenital adrenal hyperplasia.European journal of pediatrics · 2026Article
- Dynamic change of estrogen and progesterone metabolites in human urine during pregnancy.Scientific reports · 2025Article
- Comparative- and network-based proteomic analysis of bacterial chondronecrosis with osteomyelitis lesions in broiler's proximal tibiae identifies new molecular signatures of lameness.Scientific reports · 2023Article
- Progesterone inhibitory role on gastrointestinal motility.Physiological research · 2022Review
- The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens.Endocrine reviews · 2021Review
- Aldo-keto reductase family 1 member C1 regulates the osteogenic differentiation of human ASCs by targeting the progesterone receptor.Stem cell research & therapy · 2021Article
- Review
- New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling.American journal of cancer research · 2021Review
- High susceptibility to collagen-induced arthritis in mice with progesterone receptors selectively inhibited in osteoprogenitor cells.Arthritis research & therapy · 2020Article
- The effect of female sex steroid hormones on osteogenic differentiation of endometrial stem cells.Molecular biology reports · 2020Article
- Article
- Strain-specific differences in the development of bone loss and incidence of osteonecrosis following glucocorticoid treatment in two different mouse strains.Journal of orthopaedic translation · 2019Article
- Sex dimorphic regulation of osteoprogenitor progesterone in bone stromal cells.Journal of molecular endocrinology · 2017Article
- Acceleration of Fracture Healing by Overexpression of Basic Fibroblast Growth Factor in the Mesenchymal Stromal Cells.Stem cells translational medicine · 2017Article
- Sex-Dependent, Osteoblast Stage-Specific Effects of Progesterone Receptor on Bone Acquisition.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
- Improved Mobilization of Exogenous Mesenchymal Stem Cells to Bone for Fracture Healing and Sex Difference.Stem cells (Dayton, Ohio) · 2016Article
- Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Article
- Article
- β-Ecdysone Augments Peak Bone Mass in Mice of Both Sexes.Clinical orthopaedics and related research · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Augmentation of the peak bone mass (PBM) may be one of the most effective interventions to reduce the risk of developing osteoporosis later in life; however treatments to augment PBM are currently limited. Our study evaluated whether a greater PBM could be achieved either in the progesterone nuclear receptor knockout mice (PRKO) or by using a nuclear progesterone receptor (nPR) antagonist, RU486 in mice. Compared to their wild type (WT) littermates the female PRKO mice developed significantly higher cancellous and cortical mass in the distal femurs, and this was associated with increased bone formation. The high bone mass phenotype was partially reproduced by administering RU486 in female WT mice from 1-3 months of age. Our results suggest that the inhibition of the nPR during the rapid bone growth period (1-3 months) increases osteogenesis, which results in acquisition of higher bone mass. Our findings suggest a crucial role for progesterone signaling in bone acquisition and inhibition of the nPR as a novel approach to augment bone mass, which may have the potential to reduce the burden of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.